VivoSeq
Other

Iron-Deficiency

0

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

Iron-deficiency is an early-stage landscape with 0 programs across 5 companies. The most active players are Eli Lilly, Sichuan Huiyu Pharmaceutical Co., Ltd, Shield Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

ApprovedS

Sichuan Huiyu Pharmaceutical Co., Ltd

0 programs

PreclinicalS

Shield Therapeutics

0 programs

PreclinicalV

Vifor Pharma

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Completed17 · 61%
Recruiting3 · 11%
Withdrawn2 · 7%
Unknown status2 · 7%
Terminated2 · 7%
Not yet recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

28 trials

Restoring Iron Deficiency in POTS
Recruiting·VVanderbilt University Medical Center·Phase 2·NCT07197905·12 enrolled
Choline and Iron Deficiency
Recruiting·UUniversity of Minnesota·Phase 2/3·NCT06527391·300 enrolled
Monoferric for Prenatal Iron Deficiency
Recruiting·OOregon Health and Science University·Phase 1·NCT05763043·80 enrolled
Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia
Not yet recruiting·UUniversity of Medicine, Mandalay·Phase 4·NCT07391371·60 enrolled
A Trial of Iron Replacement in Patients With Iron Deficiency.
Completed·—·Phase 4·NCT01067547·130 enrolled
Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia
Completed·LLaboratoire Innotech International·Phase 4·NCT04309669·167 enrolled
Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)
Completed·PPharmacosmos UK Ltd·N/A·NCT02546154·359 enrolled
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
Completed·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1·NCT06080555·84 enrolled
Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Completed·—·N/A·NCT02889133·79 enrolled
Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
Completed·SShield Therapeutics·Phase 1·NCT03181451·37 enrolled
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
Completed·UUniversity of Alabama at Birmingham·N/A·NCT02888171·60 enrolled
Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)
Completed·UUniversity Hospital, Angers·N/A·NCT03541213·55 enrolled
Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia
Completed·PPierre Fabre Medicament·Phase 1·NCT01757119·55 enrolled
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
Completed·VVifor Pharma·Phase 3·NCT01101399·19 enrolled
Iron Deficiency and FGF23 Regulation in CKD and HF
Completed·NNorthwestern University·N/A·NCT03106298·77 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)